![Stephen Yoo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Yoo
Algemeen Directeur bij Anjarium Biosciences AG
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
David Stump | M | 74 | 9 jaar | |
Argeris Karabelas | M | 71 | 9 jaar | |
Curran Simpson | M | 62 | 9 jaar | |
Daniel Tassé | M | 64 | 8 jaar | |
Ram Palanki | M | 48 | 6 jaar | |
Alexandra Glucksmann | M | 65 | 6 jaar | |
Shiva G. Fritsch | F | - | 7 jaar | |
Patrick Christmas | M | 53 | 8 jaar | |
Douglas Fambrough | M | 55 |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 jaar |
Dina Chaya | M | 52 |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 3 jaar |
Olivier Danos | M | 66 | 7 jaar | |
Bali Muralidhar | M | 44 |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | - |
Jerome W. Jackson | M | - | 9 jaar | |
Gaurav D. Shah | M | 49 |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 jaar |
Samantha Vieira | F | - |
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Luke Beshar | M | 65 | 6 jaar | |
Edgar Engleman | M | 78 | 1 jaar | |
Camille Samuels | F | 52 | 1 jaar | |
Daniel Abdun-Nabi | M | 69 | 6 jaar | |
Sara Garon Berl | F | - | 8 jaar | |
Benjamin Auspitz | M | 51 | - | |
Michael C. Gelman | M | - | - | |
John Daniel Kiser | M | - | - | |
Faraz Ali | M | 51 | 2 jaar | |
Lynne McGrath | M | 69 | 3 jaar | |
Rickey Reinhardt | M | - | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 21 | 80.77% |
Zwitserland | 5 | 19.23% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Stephen Yoo
- Persoonlijk netwerk